CN1965823B - (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound - Google Patents

(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound Download PDF

Info

Publication number
CN1965823B
CN1965823B CN2006101374074A CN200610137407A CN1965823B CN 1965823 B CN1965823 B CN 1965823B CN 2006101374074 A CN2006101374074 A CN 2006101374074A CN 200610137407 A CN200610137407 A CN 200610137407A CN 1965823 B CN1965823 B CN 1965823B
Authority
CN
China
Prior art keywords
purposes
medicine
treatment
day
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2006101374074A
Other languages
Chinese (zh)
Other versions
CN1965823A (en
Inventor
P·H·谢菲尔
G·W·穆勒
H·-W·满
C·葛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Europe Ltd
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN1965823A publication Critical patent/CN1965823A/en
Application granted granted Critical
Publication of CN1965823B publication Critical patent/CN1965823B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discused. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF- alpha or the inhibition of PDE4.

Description

(+)-2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1,3-diketone, its synthetic method and compositions thereof
The application is dividing an application of following application: the applying date: on March 20th, 2003; Application number: 03811093.8 (PCT/US03/08738); Denomination of invention: " (+)-2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1,3-diketone: using method and compositions thereof ".
1. invention field
The present invention relates to 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the using method of (+) enantiomer of 3-diketone and comprise this compound compositions.
2. background of invention
Tumor necrosis factor-alpha (TNF-α) is a kind of main cytokine that discharges when replying immunologic stimulant by the monokaryon phagocyte.Most cells processes such as TNF-α can promote for example to break up, raises, propagation and protein degradation.Under low-level, TNF-α has the protective effect that prevents infective agent, tumor and tissue injury.But TNF-α also works in numerous disease.When giving mammal or humanTNF-, TNF-α can cause or exacerbate inflammation, fever, cardiovascular effect, hemorrhage, the similar acute phase response of those reacting phases of solidifying and occurring with actute infection and shock stage.All relate to TNF-α raising or ungoverned in numerous disease and disease and generate, cancer for example is as solid tumor and blood tumor; Heart disease is as congestive heart failure; And viral infection, genetic diseases, inflammatory diseases, allergic disease and autoimmune disease.
Cyclic adenosine monophosphate (cAMP) also works in numerous disease and disease, such as but not limited to asthma, inflammation and other disease (Lowe and Cheng, Drugs of the Future, 17 (9) phases: 799-807 page or leaf, 1992).Show that the raising of cAMP level has suppressed their activation and comprised TNF-α subsequently and the release of the inflammatory mediator of NF-κ B in the inflammatory leukocytes.The cAMP level improves also can cause the lax of airway smooth muscle.
Think that the main cell mechanism of cAMP inactivation is to have destroyed cAMP (Beavo and Reitsnyder, Trends inPharm., 11 phases: 150-155 page or leaf, nineteen ninety) owing to be called as gang's isozyme of cyclic nucleotide phosphodiesterase (PDE).Known have 11 PDE family members.Now confirm, for example suppress release and the airway smooth muscle lax all especially effective (Verghese etc. of PDE IV type to the inflammation-inhibiting medium, Journal of Pharmacology andExperimental Therapeutics, 272 (3) phases: 1313-1320 page or leaf, nineteen ninety-five).Therefore, specificity suppresses the chemical compound of PDE4 (PDE IV), but inflammation-inhibiting promotes airway smooth muscle lax, and has unwanted side effect such as for example cardiovascular or antiplatelet effects etc. seldom.Under acceptable therapeutic dose, the PDF4 inhibitor that uses lacks selectivity at present.
Cancer is a kind of destructive disease that has especially, and the raising of TNF-alpha levels in the blood, there is the danger of suffering from cancer and cancer diffusion in indication. usually, cancerous cell can not be survived in the blood circulation of healthy main body, one of them reason is blood vessel and has served as the barrier that oncocyte exosmoses. but experiment in vitro shows, cytokine levels improves and can promote cancerous cell to stick on the endothelium fully. and a kind of explanation is, for example to stimulate the biosynthesis of the cell surface receptor (endotheliocyte-leukocyte adhesion molecule) that is called as ELAM-1 and express .ELAM-1 be a member that is called as in the LEC-CAMs calcium of (comprising LECAM-1 and GMP-140)-dependent cell adhesion receptor family to cytokine such as TNF-α. in the inflammatory reaction process, ELAM-1 on the endotheliocyte plays leukocyte " homing receptor ". studies show that recently, ELAM-1 on the endotheliocyte can mediate and promote colon cancer cell to stick to (Rice. etc. on the endothelium of handling with cytokine, 1989, Science, 246 phases: the 1303-1306 page or leaf).
For example arthritis, relevant arhritis conditions (for example osteoarthritis and rheumatoid arthritis), enteritis (for example Crohn disease and ulcerative colitis), sepsis, psoriasis, atopic dermatitis, contact dermatitis and inflammatory diseasess such as chronic obstructive pulmonary disease, chronic pneumonia also are general difficult diseases.In inflammatory reaction, TNF-α plays a crucial role, and gives the inflammatory diseases animal model, chronic and acute reaction capable of blocking with their antagonist.
Viral infection, hereditary, inflammatory diseases, allergic disease and autoimmune disease all relate to and improve or ungoverned TNF-α generation.These disease examples include but not limited to: HIV (HIV (human immunodeficiency virus)); Hepatitis; Adult respiratory distress syndrome; Bone absorpting disease; Chronic obstructive pulmonary disease; Chronic pneumonia; Asthma, dermatitis; Capsule sample fibrosis; Septic shock; Sepsis; Endotoxin shock; The hemodynamics shock; Sepsis syndrome; Reperfusion injury after the ischemia; Meningitis; Psoriasis; Fibrotic conditions; Cachexia; Transplant rejection; Autoimmune disease; Rheumatoid spondylitis; Arhritis conditions, for example rheumatoid arthritis and osteoarthritis; Osteoporosis; Crohn disease; Ulcerative colitis; The intestinal inflammation; Multiple sclerosis; Systemic lupus erythematosus (sle); The ENL of leprosy; Radiation damage; Asthma; Hyperoxic alveolar damage.Tracey etc., 1987, Nature, 330 phases: 662-664 page or leaf and Hinshaw etc., nineteen ninety, Circ.Shock, 30 phases: 279-292 page or leaf (endotoxin shock); Dezube etc., nineteen ninety, Lancet, 335 phases: 662 pages (cachexia); Millar etc., 1989, Lancet, 2 phases: 712-714 page or leaf and Ferrai-Baliviera etc.,, Arch.Surg., 124 phases: 1400-1405 page or leaf (adult respiratory distress syndrome) in 1989; Bertolini etc., 1986, Nature, 319 phases: 516-518 page or leaf, Johnson etc., 1989,124 phases of Endocrinology: 1424-1427 page or leaf, Holler etc., nineteen ninety, Blood, 75 phases: 1011-1016 page or leaf and Grau etc., 1989, N.Engl.J.Med., 320 phases: 1586-1591 page or leaf (bone absorpting disease); Pignet etc., nineteen ninety, Nature, 344 phases: 245-247 page or leaf, Bissonnette etc.,, Inflammation, 13 phases: 329-339 page or leaf and Baughman etc., nineteen ninety, J.Lab.Clin.Med., 115 phases: 36-42 page or leaf (chronic pneumonia) in 1989; Elliot etc., nineteen ninety-five, Int.J.Pharmac., 17 phases: 141-145 page or leaf (rheumatoid arthritis); Von Dullemen etc., nineteen ninety-five, Gastroenterology, 109 phases: 129-135 page or leaf (Crohn disease); Duh etc., 1989, Proc.Nat.Acad.Sci., 86 phases: 5974-5978 page or leaf, Poll etc., nineteen ninety, Proc.Nat.Acad.Sci., 87 phases: 782-785 page or leaf, Monto etc., nineteen ninety, Blood, 79 phases: 2670 pages, Clouse etc., 1989, J.Immunol., 142 phases: 431-438 page or leaf, Poll etc., 1992, AIDS Res.Hum.Retrovirus, 191-197 page or leaf, Poli etc., nineteen ninety, Proc.Natl.Acad.Sci., 87 phases: 782-784 page or leaf, Folks etc., 1989, PNAS, 86 phases: 2365-2368 page or leaf (opportunistic infection that HIV and HIV cause).
Some cytokine of the TNF-of comprising α capable of blocking active or suppress the medicine of its generation will be useful therapeutic agent.Verified, many micromolecular inhibitors can treat or prevent to relate to TNF-α inflammatory diseases (referring to the summary of Lowe, 1998, Exp.Opin.Ther.Patents, 8 phases: the 1309-1332 page or leaf).This molecule is a United States Patent (USP) 6,020, the phenethyl sulfone compound of the replacement of No. 358 descriptions.
3. summary of the invention
The present invention relates to use the enantiomer of phenethyl sulphones of replacement and the method for the acceptable salt of pharmacy, hydrate, solvate, clathrate, prodrug and polymorph treatment disease and disease thereof, and the method that reduces mammiferous cytokine and precursor level thereof.The present invention also relates to comprise 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, a kind of enantiomer of 3-diketone and the Pharmaceutical composition of pharmaceutically acceptable carrier.The invention still further relates to 2-[1-(3-ethyoxyl-4-the methoxyphenyl)-2-mesyl ethyl that is substantially free of other enantiomer]-4-acetylamino isoindoline-1, a kind of enantiomer of 3-diketone.
The present invention be more particularly directed to 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; (+) enantiomer of 3-diketone. with its raceme--2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; the 3-diketone is compared, and thinks that this chemical compound has usefulness and other advantage of raising.
The present invention includes 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, (+) enantiomer of 3-diketone is in treatment or prevent the mammiferous disease that can improve by the generation that suppresses TNF-α or the purposes in the disease.In certain embodiment, described treatment comprises reduction or eliminates side effect.These diseases include but not limited to cancer, include but not limited to head cancer, thyroid carcinoma, neck cancer, cancer eye, skin carcinoma, oral cancer, laryngocarcinoma, esophageal carcinoma, breast cancer, osteocarcinoma, leukemia, bone marrow cancer, pulmonary carcinoma, colon cancer, carcinomaofsigmoid, rectal cancer, gastric cancer, carcinoma of prostate, breast carcinoma, ovarian cancer, renal carcinoma, hepatocarcinoma, cancer of pancreas, the brain cancer, intestinal cancer, heart cancer, adrenal carcinoma, subcutaneous tissue cancer, lymph node cancer, heart cancer, and combination.The concrete cancer of available described method treatment has multiple myeloma, malignant melanoma, glioblastoma, leukemia and solid tumor.
The present invention also comprises 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; (+) enantiomer treatment of 3-diketone or the following cardiopathic purposes of prevention, described heart disease include but not limited to septic shock, acute viral myocarditis, the repulsion of the heart value of moving and the myocardial infarction of congestive heart failure, cardiomyopathy, pulmonary edema, endotaxin mediate.
The present invention also comprises 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, (+) enantiomer of 3-diketone can be by suppressing disease that PDE4 improves or the purposes in the disease in treatment.For example, chemical compound of the present invention and compositions can be used for treatment or prophylaxis of viral infections, genetic diseases, inflammatory diseases, allergic disease and autoimmune disease.These disease examples include but not limited to: HIV; Hepatitis; Adult respiratory distress syndrome; Bone absorpting disease; Chronic obstructive pulmonary disease; Chronic pneumonia; Dermatitis; Inflammatory dermatosis, atopic dermatitis, Cystic fibrosis; Septic shock; Sepsis; Endotoxin shock; The hemodynamics shock; Sepsis syndrome; Reperfusion injury after the ischemia; Meningitis; Psoriasis; Fibrotic conditions; Cachexia; The value of moving that comprises graft versus host disease is repelled; Autoimmune disease; Rheumatoid spondylitis; Arhritis conditions, for example rheumatoid arthritis and osteoarthritis; Osteoporosis; Crohn disease; Ulcerative colitis; The intestinal inflammation; The multiple sclerosis disease; Systemic lupus erythematosus (sle); Erythema nodosum leprosum in the leprosy (ENL); Radiation damage; Asthma and the damage of hyperoxic alveolar.
In another embodiment; 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the stereoisomer of 3-diketone pure (+) enantiomer also can be used for treatment or prophylaxis of microbial infects or infected by microbes syndrome (including but not limited to the opportunistic infection that bacterial infection, fungal infection, malaria, mycobacterium infection and HIV cause).
The present invention also comprise comprise 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the Pharmaceutical composition and the unit dosage forms of a kind of enantiomer of 3-diketone and the acceptable polymorph of pharmacy, prodrug, salt, hydrate, clathrate and solvate.
In an independent embodiment, the present invention includes 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, (+) enantiomer of 3-diketone.
In a further embodiment; the present invention includes a kind of preparation 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; the method of the pure enantiomer of stereoisomer of 3-diketone; said method comprising the steps of: with 1-(3-ethyoxyl-4-methoxyl group-phenyl)-2-mesyl-ethamine and chiral amino acid reaction; then with the product and the N-(1 of the first step; 3-dioxo-1; 3-dihydro-isobenzofuran-4-yl)-and the acetamide reaction. in a relevant embodiment, the present invention includes the chirality salt of 1-(3-ethyoxyl-4-methoxyl group-phenyl)-2-mesyl-ethamine.
3.1. accompanying drawing summary
Fig. 1 illustrates 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the preparation of (+) enantiomer of 3-diketone.
Fig. 2. illustrate the effect of enantiomer of the present invention to the inductive neutrocytophilia of LPS-on the lung of sentient ferret.
3.2. definition
Term used herein " compd A " refers to that eluent is 15: 85 ethanol: 20mM KH when using chromatographic column to be 150mm * 4.6mm Ultron Chiral ES-OVS chirality HPLC post (Agilent Technology)2PO 4(pH is 3.5), when the observation wavelength was 240nm, the HPLC post was at the pure 2-[1-of about stereoisomer that eluted in 25.4 minutes (3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylamino isoindoline-1, the 3-diketone. Compd A1The HNMR spectral data is substantially as follows:
δ(CDCl 3)：1.47(t，3H)，2.26(s，3H)，2.87(s，3H)，3.68-3.75(dd，1H)，3.85(s，3H)，4.07-4.15(q，2H)，4.51-4.61(dd，1H)，5.84-5.90(dd，1H)，6.82-8.77(m，H)，9.46(s，1H).
Compd A13C NMR spectral data is substantially as follows:
δ(DMSO-d 6)：14.66，24.92，41.61，48.53，54.46，55.91，64.51，111.44，112.40，115.10，118.20，120.28，124.94，129.22，131.02，136.09，137.60，148.62，149.74，167.46，169.14，169.48.
The compd A that is dissolved in methyl alcohol also makes linearly polarized light to the deflection of (+) direction.
Bound by theory does not think that compd A is S-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylamino isoindoline-1, the 3-diketone }, its structure is as follows:
Term used herein " patient " refers to mammal, refers to especially the people.
Term used herein " the acceptable salt of pharmacy ", referring to by the acceptable nontoxic acid of pharmacy or the salt of alkali (comprising inorganic bronsted lowry acids and bases bronsted lowry and organic bronsted lowry acids and bases bronsted lowry) preparation. the acceptable base addition salts of the pharmacy of suitable compound of the present invention comprises by aluminium, calcium, lithium, magnesium, potassium, the slaine of sodium and zinc preparation or the organic salt that is prepared by following organic base: lysine, N, N '-dibenzyl-ethylenediamin, chloroprocanine, choline, diethanol amine, ethylenediamine, meglumine (N-methyl glucoside amine) and procaine. suitable non-toxic acid includes but not limited to following inorganic acid and organic acid: acetic acid for example, alginic acid, ortho-aminobenzoic acid, benzene sulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, vinyl sulfonic acid, formic acid, fumaric acid, furancarboxylic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, glactaric acid, nitric acid, pounce on acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, butanedioic acid, sulfanilic acid, sulfuric acid, tartaric acid and p-methyl benzenesulfonic acid. hydrochloric acid particularly, hydrobromic acid, phosphoric acid, the non-toxic acid such as sulfuric acid and methanesulfonic acid. therefore, the example of special salt has hydrochloride and mesylate.
Unless otherwise indicated, otherwise term used herein " prodrug " means by down other of hydrolysis, oxidation or biotic environment (body in or external) and reacts, and the compound derivatives of this chemical compound can be provided.The example of prodrug includes but not limited to the derivant and the metabolite of compd A, but this material comprises the biological hydrolysis part, but but but but but but the phosphate ester analog of the uride of the carbonic ester biological hydrolysis of the carbamate biological hydrolysis of the ester biological hydrolysis of the amide biological hydrolysis of biological hydrolysis and biological hydrolysis for example.Prodrug generally can prepare by those well-known process of describing in 1 Burger ' sMedicinal Chemistry and Drug Discovery for example (Manfred E.Wolff edit, the 5th edition, nineteen ninety-five) 172-178 page or leaf, the 949-982 page or leaf.
Unless otherwise indicated, otherwise term used herein " but amide of biological hydrolysis ", " but ester of biological hydrolysis ", " but carbamate of biological hydrolysis ", " but carbonic ester of biological hydrolysis ", " but uride of biological hydrolysis ", " but phosphate ester of biological hydrolysis " respectively refer to amide, ester, carbamate, carbonic ester, uride or the phosphate ester of a certain chemical compound, but these biological hydrolysis parts: 1) do not influence the biological activity of described chemical compound, but can give chemical compound favourable body internal characteristic, for example absorption, continuous action or play a role; Or 2) do not have biological activity, but can be converted into biological activity in vivo.But the example of the ester of biological hydrolysis includes but not limited to, lower alkyl esters, alkoxyl acid esters, alkyl amido Arrcostab and cholinester.But the example of the amide of biological hydrolysis includes but not limited to, low alkyl group amide, alpha-amino acid amides, alkoxyl amide and alkylamino alkyl carbonyl amide.But the example of the carbamate of biological hydrolysis includes but not limited to: the ethylenediamine of low-grade alkylamine, replacement, aminoacid, hydroxy alkyl amine, heterocyclic amine and assorted arylamine and polyetheramine.
Unless otherwise indicated, otherwise term used herein " stereoisomer is pure " mean a kind of stereoisomer of inclusion compound and be substantially free of the compositions of other stereoisomer of this chemical compound.For example, the pure compositions of stereoisomer with chemical compound of a chiral centre is substantially free of the opposite enantiomer of described chemical compound.The pure compositions of stereoisomer with chemical compound of two chiral centres is substantially free of other diastereomer of described chemical compound.The chemical compound that stereoisomer is pure generally comprises approximately other stereoisomer that is less than the described chemical compound of 20% weight greater than a kind of stereoisomer peace treaty of the described chemical compound of 80% weight, other stereoisomer that more preferably from about is less than the described chemical compound of 10% weight greater than a kind of stereoisomer peace treaty of the described chemical compound of 90% weight, even more preferably from about be less than other stereoisomer of the described chemical compound of 5% weight greater than a kind of stereoisomer peace treaty of the described chemical compound of 95% weight, most preferably from about be less than other stereoisomer of the described chemical compound of 3% weight greater than a kind of stereoisomer peace treaty of the described chemical compound of 97% weight.
Unless otherwise indicated, otherwise term used herein " enantiomeric pure " means the pure compositions of stereoisomer of the chemical compound with a chiral centre.
Term used herein " side effect " includes but not limited to: gastrointestinal, kidney and liver toxicity, leukopenia, the bleeding time that causes owing to for example thrombocytopenia prolongs, gestation prolongs, feel sick, vomiting, drowsiness, unable, dizziness, teratogenesis, extrapyramidal symptom is cathisophobiaed, and comprises the cardiac toxicity of cardiovascular dysfunction, inflammation, the raising of male sexual disorder and serum liver enzyme level. term " gastrointestinal toxicity " includes but not limited to gastroenteritic ulcer and erosion. term " nephrotoxicity " includes but not limited to that for example mamillary is downright bad and the disease of chronic interstitial nephritis.
Unless otherwise indicated, otherwise term used herein " reduces or eliminates side reaction " means the seriousness that reduces one or more side reactions that define herein.
Should be noted that if the structure of describing and provide between the title of this structure and have deviation, the structure of description has bigger weight.In addition, if the spatial chemistry characteristic of for example thick line of no use or dotted line description architecture or structure division, described structure or structure division are interpreted as the stereoisomer that comprises that they are all.
4. detailed Description Of The Invention
The present invention relates to the pure compd A of stereoisomer; compd A is 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; a kind of enantiomer of 3-diketone; basically do not give up other isomer, the invention still further relates to the new using method and the compositions that comprises the pure compd A of stereoisomer of the pure compd A of stereoisomer.For example, the present invention includes compd A adds to external purposes and with compd A in vivo and is used for the treatment of and prevents in the Pharmaceutical composition and unit dosage forms of multiple disease and disease.Level by reducing TNF-α or suppress disease and the disease that PDE4 is improved for known in the art, and is described in this article.Concrete grammar of the present invention reduces or eliminates and the relevant side reaction of using as the TNF-alpha inhibitor of chemical compound.Other concrete grammar reduction of the present invention or elimination and racemic 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the side reaction that the use of 3-diketone is relevant.
Concrete grammar of the present invention comprises that treatment or prevention include but not limited to the method for disease such as solid tumor cancer, the deutero-cancer of blood and inflammatory diseases and disease.
The medicine and the dosage form of inclusion compound A of the present invention or the acceptable polymorph of its pharmacy, prodrug, salt, clathrate, solvate or hydrate can be used in the method for the present invention.
Bound by theory does not believe that compd A can suppress TNF-α and generate.Therefore, first embodiment of the present invention relates to the method that a kind of NF-of inhibition α generates, and said method comprising the steps of: the compd A that the stereoisomer of effective dose is pure or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate with show the cells contacting that TNF-α generates abnormality.In a special embodiment, the present invention relates to the method that a kind of TNF-of inhibition α generates, said method comprising the steps of: the compd A that the stereoisomer of effective dose is pure or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or the clathrate mammalian cell unusual with showing TNF-α generation contacts.
What the present invention also relates to a kind of treatment or prevention patient can be by reducing the method for the disease that the TNF-alpha levels improves, described method comprises patient treatment that needs these treatments or prevention or the pure compd A of stereoisomer that prevents effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate.
The cancer that another embodiment of the invention relates to a kind of treatment or prevention patient (includes but not limited to solid tumor, blood tumor, leukemia, multiple myeloma particularly) method, described method comprises needs the pure compd A of the stereoisomer of the patient treatment of these treatments or prevention effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate; Particularly wherein said patient is a mammal.
In another embodiment, the present invention relates to the method for a kind of PDE4 of inhibition, said method comprising the steps of: the compd A that the stereoisomer of effective dose is pure, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate contact with PDE4.
In another embodiment, the present invention relates to a kind of method of controlling cAMP level in the cell, said method comprising the steps of: the compd A that the stereoisomer of effective dose is pure, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate and cells contacting.Term used herein " control cAMP level " comprises and prevents or reduce intracellular cyclic adenosine monophosphate (cAMP) destructive rate or improve intracellular cyclic adenosine monophosphate level that wherein said cell is preferably mammalian cell, more preferably people's cell.In a kind of special method, to compare with the destructive rate of the control cells that does not contact with chemical compound of the present invention, the cAMP destructive rate reduces about 10,25,50,100,200 or 500%.
What another embodiment of the invention related to a kind of treatment or prevention patient can be by suppressing the disease that PDE4 improves or the method for disease, described method comprises patient treatment that needs these treatments or prevention or the pure compd A of stereoisomer that prevents effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate.Include but not limited to asthma, inflammation (for example because the inflammation that causes of perfusion) again, chronic or acute occlusion pneumonopathy, chronic or acute pneumonia, enteritis, Crohn disease, Behcet disease (Bechet ' s) or colitis by suppressing disease that PDE4 improves.
Another embodiment of the present invention relates to a kind of treatment or prevention patient's the following disease or the method for disease: depression, asthma, inflammation (contact dermatitis for example, atopic dermatitis, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory dermatosis, owing to pour into the inflammation that causes again), chronic or acute occlusion pneumonopathy, chronic or acute pneumonia, enteritis, Crohn disease, Behcet disease or colitis, described method comprises patient treatment that needs these treatments or prevention or the pure compd A of stereoisomer that prevents effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate; Particularly wherein said patient is a mammal.
An independent embodiment of the present invention comprises the method for treatment or prevention myelodysplastic syndrome (MDS), described method comprises patient treatment that needs these treatments or prevention or the pure compd A of stereoisomer that prevents effective dose, or the acceptable salt of its pharmacy, solvate, hydrate, stereoisomer, clathrate or prodrug.MDS means different types of hematopoietic stem cell disease.MDS is characterised in that because invalid hemopoietic, causes cytopenia and the uncertain danger that is converted into acute leukemia in the cell bone marrow, peripheral blood of form and maturation defect (medullary cell generation obstacle).Referring to The Merck Manual, 953 pages (17 editions, 1999) and List etc., nineteen ninety, J.Clin.Oncol., 8 phases: 1424 pages, MDS.
An independent embodiment of the present invention comprises the method for treatment or prevention myeloproliferative diseases (MPD), described method comprises patient treatment that needs these treatments or prevention or the pure compd A of stereoisomer that prevents effective dose, or the acceptable salt of its pharmacy, solvate, hydrate, stereoisomer, clathrate or prodrug.Myeloproliferative diseases (MPD) is meant that with hematopoietic stem cell system be a class disease of feature unusually.Referring to, CurrentMedical Diagnosis ﹠amp for example; Trheatment, 499 pages (37 editions, Tierney etc. write, Appleton﹠amp; Lange, 1998).
The present invention also comprises a kind of treatment, prevention or handles the syndromic method of plyability regional pain, described method comprises the pure compd A of stereoisomer that needs these treatments, prevention or the patient treatment of handling or prevention effective dose, or the acceptable salt of its pharmacy, solvate, hydrate, stereoisomer, clathrate or prodrug.In a specific embodiment, before the operation or physical therapy of the syndromic symptom of plyability regional pain that can directly reduce or eliminate the patient, during or the back administration.
In adhoc approach of the present invention, the compd A that stereoisomer is pure or the acceptable polymorph of its pharmacy, prodrug, salt, solvate, hydrate or clathrate and at least a other therapeutic agent administering drug combinations.Other therapeutic agent example includes but not limited to anticarcinogen, anti-inflammatory agent, antihistaminic and decongestant.
4.1. Synthesize and preparation
Adopt United States Patent (USP) the 6th; the method of describing for 020, No. 358 can easily prepare racemic 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; the 3-diketone, this patent is bonded to herein by reference.
By this area prior art, can in its racemic compound, isolate compd A.Example includes but not limited to the use of formation, chirality and high performance liquid chromatography " HPLC " of chirality salt and the formation and the crystallization of chirality salt.Referring to, Jacques for example, J. etc., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S.H. etc., Tetrahedron, 33 phases: 2725 pages (1977); Eliel, E.L., Stereochemistryof Carbon Compounds (McGraw-Hill, New York, 1962), and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions, 268 pages (E.L.Eliel writes, Notre Dame university press, Notre Dame, IN, 1972).
In a concrete method, compd A can be synthetic by 3-acetylamino phthalic anhydride and (S)-2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine.(S)-the chiral amino hydrochlorate of 2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine includes but not limited to the salt that becomes with following amino acid whose L isomer: alanine; arginine; agedoite; aspartic acid, cysteine, glutamine; glutamic acid; glycine, histidine, isoleucine; leucine; lysine, methionine, phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; ornithine; the 4-aminobutyric acid; the 2-aminoisobutyric acid; the 3-alanine; ornithine; nor-leucine; norvaline; hydroxyproline, sarcosine, citrulline; cysteic acid; tert-butyl group glycine; tert-butyl group alanine, phenylglycine, Cyclohexylalanine and N-acetyl group-leucine.A kind of concrete chiral amino hydrochlorate is (S)-2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine-N-acetyl group-L-leucine salt, and it is decomposed into 2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine and N-acetyl group-L-leucine in methanol.
4.2. Therapeutic Method
What the present invention includes treatment and prevention patient can be by reducing the disease that the TNF-alpha levels improves or the method for disease, described method comprises needs the pure compd A of the stereoisomer of the patient treatment of these treatments or prevention effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate.
The disease of improving by inhibition TNF-α includes but not limited to: heart disease, and for example congestive heart failure, cardiomyopathy, pulmonary edema, the septic shock of endotoxin-adjusting, acute viral myocarditis, heart transplantation is repelled, and myocardial infarction; Solid tumor includes but not limited to sarcoma, cancer, fibrosarcoma, myxosarcoma, lipoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovioma, mesothelioma, ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, cancer of pancreas, breast carcinoma, ovarian cancer, carcinoma of prostate, squamous cell cancer, basal cell carcinoma, adenocarcinoma, syringocarcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, cancer of biliary duct, choriocarcinoma, spermocytoma, embryonal carcinoma, wilms' tumor, cervical cancer, testicular tumor, pulmonary carcinoma, small cell lung cancer, bladder cancer, epithelial cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, Oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma; With the blood tumor, include but not limited to acute lymphoblastic leukemia " ALL ", B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, acute myeloid leukemia " AML ", acute promyelocytic leukemia " APL ", acute monocytic leukemia, Di Guglielmo syndrome (erythroleukemic leukemia), acute megakaryoblast property leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute nondifferentiated leukemia, chronic myelocytic leukemia " CML ", chronic lymphocytic leukemia " CLL ", hairy cell leukemia, multiple myeloma and acute and chronic leukemia, for example lymphoblast property, bone marrow, lymphatic and myelocytic leukemia.
The concrete method of the present invention also comprises and gives other therapeutic agent (i.e. therapeutic agent except that compd A).Other therapeutic agent example includes but not limited to: anticarcinogen, and such as but not limited to alkylating agent, chlormethine, aziridine, methylmelamine, alkyl sulfonate esters, nitroso ureas, triazenes, folacin, pyrimidine analogue, purine analogue, vinca alkaloids, epipodophyllotoxin, antibiotic, topoisomerase enzyme inhibitor and anti-cancer vaccine.
What the present invention further comprised a kind of treatment or prevention patient can be by suppressing the disease that PDE4 improves or the method for disease, described method comprises needs the pure compd A of the stereoisomer of the patient treatment of these treatments or prevention effective dose, or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate.The disease of improving by inhibition PDE4 includes but not limited to: asthma, inflammation, chronic or acute occlusion pneumonopathy, chronic or acute occlusion pneumonia, enteritis, Crohn disease, Behcet disease, colitis, ulcerative colitis and arthritis or because the inflammation that causes of perfusion again.In a preferred embodiment, disease or disease to be treated or prevention are chronic obstructive pulmonary disease.
Concrete grammar of the present invention can comprise and gives a kind of other therapeutic agent such as but not limited to anti-inflammatory agent, antihistaminic and decongestant. the example of these other therapeutic agents includes but not limited to: antihistaminic, include but not limited to ethylaminoethanol, ethylenediamine, piperazine and phenothiazine; Anti-inflammatory agent; NSAID (non-steroidal anti-inflammatory drug) (NSADS) includes but not limited to aspirin, Salicylate (ester), acetyl aminophenol, indomethacin, sulindac, etodolac, fenamates, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, Evil promazine, piroxicam, meloxicam, pyrazolone derivative; And steroidal compounds, include but not limited to corticosteroid and adrenocortical steroid.
Concrete grammar of the present invention eliminate or reduce drug-drug interactions with other be used for the treatment of the relevant side effect of these treatment of conditions agent (comprising racemic substituted benzene ethyl sulfone).Be not subjected to the restriction of any theory; compare racemic 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; the 3-diketone, the compd A that stereoisomer is pure can further provide the treatment effectiveness or the therapeutic index of comprehensive raising.For example in some cases, give more a spot of described medicine and can obtain identical therapeutic effect.
As mentioned above, reactive compound of the present invention (the being compd A) disease and the disease that can be used for treating or preventing wide region.But, when disease or disease are carried out acute or long-term treatment, according to the character and the seriousness of described disease or disease, and the route of administration of active component, the treatment of given activity component of the present invention or preventive dose big young pathbreaker change.Different according to age, body weight and individual patient reaction, dosage, perhaps administration number of times also will change.After these factors were considered fully, those skilled in the art can easily select suitable medication.For disease described herein, generally recommend the every day dosage range to be about 1mg-1000mg, single dose administration, every day 1 time, preferred gradation administration every day.More particularly, with every day dosage on average separate administration at twice.Specifically, every day, dosage range should be about 5mg-500mg, more particularly, was about 10mg-200mg every day.Specifically, every day, dosage can give the dosage form of 5mg, 10mg, 15mg, 20mg, 25mg, 50mg or 100mg.In treatment during the patient, should be from lower dosage begin treatment, perhaps every day about 1mg-25mg, if desired, can increase to and reach 200mg-1000mg every day approximately, according to patient's general reaction, can also graded administration of single dose administration.Equally, every day, dosage can be 0.01mg/kg-100mg/kg.
In some case, may need to use the active component that exceeds dosage range disclosed herein, this is conspicuous to those of ordinary skills.It should be noted that in addition that after reaction how and when clinicist or attending doctor will know is ended, adjusting or stopped treatment in conjunction with individual patient.
Term used herein " treatment effective dose ", " prevention effective dose " and " treatment or prevention effective dose " comprise above-mentioned dosage and administration number of times arrangement.Those of ordinary skill in the art will learn easily that different treatment effective doses are applicable to different diseases and disease.Equally; above-mentioned dosage and administration number of times arrangement also comprise enough treatments or prevent these diseases; but be not enough to cause or be enough to and reduce and racemic 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the dosage of the side reaction that the 3-diketone is relevant.
4.3. Pharmaceutical composition
The present invention includes the Pharmaceutical composition and the unit dosage forms of inclusion compound A or the acceptable polymorph of its pharmacy, prodrug, salt, solvate, hydrate or clathrate.Single dosage form of the present invention is applicable to oral administration, mucosa (comprising rectum, nose or vagina), parenteral (comprising subcutaneous, muscle, disposable large bolus injection, tremulous pulse or vein), Sublingual, percutaneous, mouthful cheek or topical.
Pharmaceutical composition of the present invention and dosage form comprise the pure compd A of stereoisomer or its pharmacy acceptable prodrugs, metabolite, polymorph, salt, solvate, hydrate or clathrate.Pharmaceutical composition of the present invention and dosage form generally also comprise the acceptable excipient of one or more pharmacy.
A kind of special Pharmaceutical composition that this embodiment comprises comprises the pure compd A of stereoisomer, or the acceptable polymorph of its pharmacy, prodrug, salt, solvate, hydrate or clathrate and at least a other therapeutic agent.The example of other therapeutic agent includes but not limited to those cancer therapy drugs and the anti-inflammatory drug that above-mentioned 4.2. partly lists.
Unit dosage forms of the present invention is applicable to per os, mucosa (for example nose, Sublingual, vagina, mouthful cheek or rectum), parenteral (for example subcutaneous, vein, disposable large bolus injection, muscle or tremulous pulse) or transdermal administration patient. the example of dosage form includes but not limited to: tablet; Caplet; Capsule, for example soft elastic gelatin capsule agent; Cachet; Lozenge (troches); Lozenge (lozenges); Dispersant; Suppository; Ointment; Paste (paste); Paste; Powder; Dressing; Ointment; Plaster; Solution; Patch; Aerosol (for example nasal spray or inhalant); Gel; Be applicable to that per os or through mucous membrane give patient's liquid dosage form, comprise suspensoid (for example aqueous or non-aqueous suspensoid, oil-in-water emulsion or water-in-oil type liquid emulsion), solution, and elixir; Be applicable to the liquid dosage form that gives the patient through parenteral; Be applicable to the sterile solid dosage form (for example crystallization or amorphous solid) that gives patient's liquid dosage form through parenteral with rebuilding to provide.
The composition of dosage form of the present invention, shape and type generally will change according to their purposes.For example, when being used for the treatment of inflammation or associated conditions, compare the dosage form of long-term treatment, the dosage form of acute treatment can comprise more one or more described active components.Similarly, when being used for the treatment of same disease or disease, the amount of one or more described active components that comprise than peroral dosage form through the dosage form of parenteral is lacked.The various aspects of the concrete dosage form that the present invention includes are all inequality, and this will be readily apparent to persons skilled in the art.Referring to, Remington ' s Pharmaceutical Sciences for example, 18 editions, Mack publishes, Easton PA (nineteen ninety).
Pharmaceutical composition and dosage form generally comprise one or more excipient.The pharmaceutics those skilled in the art know suitable excipient, and the example of the suitable excipient that this paper provided is not limited to this.Whether a kind of special excipient is fit to add in Pharmaceutical composition or the dosage form, will be according to multiple factor well known in the art, include but not limited to that the approach etc. that described dosage form is given the patient determines.For example, peroral dosage form such as tablet can comprise the excipient that is not suitable for parenteral dosage forms.The suitability of special excipient also can be determined according to the concrete active component in the described dosage form.
Lactose-free compositions of the present invention can comprise various excipient well known in the art, and is listed in the excipient among American Pharmacopeia (USP) SP (XXI)/NF (XVI) for example.Lactose-free compositions generally comprises active component, but pharmacy is compatible and binding agent/the filler of pharmacy receiving amount and lubricant.Preferred lactose-free dosage form comprises active component, microcrystalline Cellulose, pregelatinized Starch and magnesium stearate.
The present invention further comprises anhydrous Pharmaceutical composition and the dosage form that comprises active component, because water can make some chemical compounds decompose easily.For example, for the character of the long-time stability of determining effect duration for example or preparation, accept extensively at pharmaceutical field and to add the method for entry (for example 5%) as simulate long storage.Referring to, Jens T.Carstensen for example, Drug Stability:Principles ﹠amp; Practice, 2 editions, Marcel Dekker, New York, New York, nineteen ninety-five, 379-80 page or leaf.In fact, water and Re Ke quicken the decomposition of some chemical compounds.Because in the process of preparation production, processing, packing, storage, transportation and use, often run into moisture and/or humidity problem, therefore, moisture is for the highly significant that influences of preparation.
Use anhydrous or component that water content is low and in the environment of low moisture or low humidity, can prepare anhydrous Pharmaceutical composition of the present invention and dosage form.If need frequent contact wetting and/or humidity at production, packing and/or storage process, the Pharmaceutical composition and the dosage form that then preferably comprise lactose and at least a active component (comprising primary amine or secondary amine) are anhydrous.
The preparation of anhydrous Pharmaceutical composition and storage should keep its no aqueous nature.Correspondingly, preferred anhydrous composition uses known waterproof material packing, so that the kit packing of their available suitable regulations.Suitable packing example includes but not limited to sealed foil, plastics, single dose container (for example phial), blister package and splits packing.
The present invention further comprises Pharmaceutical composition and the dosage form that contains one or more chemical compounds that can reduce the active component decomposition rate.These chemical compounds that are called " stabilizing agent " herein include but not limited to antioxidant, as ascorbic acid, pH buffer agent or salt buffer agent.
Amount with excipient is the same with kind, the amount of active component can be according to changing such as but not limited to the different of factors such as approach that give the patient with concrete kind in the dosage form. but representative dosage form inclusion compound A of the present invention, or the acceptable salt of its pharmacy, solvate, clathrate, hydrate, polymorph or prodrug, every day, dosage range was about 1mg-1000mg, single dose administration in the morning, once a day, but preferred gradation administration every day, with the food administration. more particularly, with every day dosage on average separate, gradation administration every days two. specifically, every day, dosage range should be about 5mg-500mg; More particularly, be about 10mg-200mg. every day in treatment during the patient, should from every day about 1mg-25mg than the low dosage begin treatment, and if desired, dosage every day can be increased to the highest about 200mg-1000mg, according to patient's general reaction, but single dose administration also can the gradation administration.
4.3.1. Peroral dosage form
The Pharmaceutical composition of the present invention that is applicable to oral administration can be for discrete dosage form, such as but not limited to tablet (for example chewable tablet), Caplet, capsule and liquid preparation (for example syrup of seasoning).These dosage forms comprise the active component of the amount of pre-determining, and can be by practice of pharmacy preparation well known to those skilled in the art.Mainly referring to Remington ' sPharmaceutical Sciences, 18 editions, Mack publishes, Easton PA (nineteen ninety).
According to conventional pharmaceutical compounding technology,, prepare representative peroral dosage form of the present invention with active component and the abundant mixing of at least a excipient.According to the dosage form of administration needs, excipient can be various forms.For example, the excipient that is applicable to liquid oral dosage form or aerosol includes but not limited to water, dihydroxylic alcohols, oil, alcohol, correctives, antiseptic and coloring agent.The excipient example that is applicable to solid oral dosage form (for example powder, tablet, capsule and Caplet) includes but not limited to starch, sugar, microcrystalline Cellulose, diluent, granulating agent, lubricant, binding agent and disintegrating agent.
Because convenient drug administration, tablet and capsule are the most frequently used peroral dosage form that wherein uses solid excipient.If desired, water that can be by standard or non-water technology are to tablet coating.Can prepare these dosage forms by any practice of pharmacy.Pharmaceutical composition and dosage form be preparation by the following method generally: with active component and liquid-carrier, fine-grained solids carrier or both abundant mixings, product can be made needed shape when needed then.
For example, can prepare tablet by compression and mold pressing.Compressed tablet can be by active component (optional and mixed with excipients) the compression preparation in suitable machine with free-flowing form (as powder or particle form).Molded tablet can pass through the mixture mold pressing preparation in suitable machine with the powder compound of inert liquid diluent moistening.
The example that can be used for the excipient of peroral dosage form of the present invention includes but not limited to binding agent, filler, disintegrating agent and lubricant.The binding agent that is applicable to Pharmaceutical composition and dosage form includes but not limited to: corn starch, potato starch or other starch, gelatin, natural and synthetic natural gum (as arabic gum), sodium alginate, alginic acid, other alginate, the powdery tragacanth, guar gum, cellulose and derivant thereof (for example ethyl cellulose, cellulose acetate, carboxymethylcellulose calcium, sodium carboxymethyl cellulose), polyvinylpyrrolidone, methylcellulose, pregelatinized Starch, hydroxypropyl emthylcellulose (for example No. 2208, No. 2906, No. 2910), microcrystalline Cellulose, and composition thereof.
The example that is applicable to the filler of Pharmaceutical composition disclosed herein and dosage form includes but not limited to: Pulvis Talci; calcium carbonate (for example granule or powder), microcrystalline Cellulose, Powderd cellulose; dextrates; Kaolin, mannitol, silicic acid; sorbitol; starch, pregelatinized Starch, and composition thereof.Binding agent in the Pharmaceutical composition of the present invention or filler generally account for about 50%-99% weight of described Pharmaceutical composition or dosage form.
The microcrystalline Cellulose that is fit to form includes but not limited to: with AVICEL-PH-101, AVICEL-PH-103AVICEL RC-581, AVICEL-PH-105 (from FMCCorporation, American Viscose Division, Avicel Sales, Marcus Hook, PA) commodity of Chu Shouing, and composition thereof.Concrete binding agent is with the microcrystalline Cellulose of AVICEL RC-581 sale and the mixture of sodium carboxymethyl cellulose.The excipient or the additive of suitable anhydrous or low water content comprise AVICEL-PH-103 TmWith Starch 1500LM.
In the time of in being exposed to aqueous environment, the disintegrating agent that is used for compositions of the present invention can make disintegration of tablet. contain sector-meeting disintegrate when storing of too many disintegrating agent, those sheets that contain disintegrating agent very little then can not be with the speed disintegrate of needs or can not disintegrate under the condition of needs. therefore, should use capacity (both not many also not very little, can not change the release of described active component) disintegrating agent prepare solid oral dosage form of the present invention. the consumption of disintegrating agent changes according to dosage form is different, to those skilled in the art, this is readily appreciated that. Pharmaceutical composition generally comprises about 0.5-15% weight, be specially the disintegrating agent of about 1%-5% weight.
The disintegrating agent that can be used for Pharmaceutical composition of the present invention and dosage form includes but not limited to: agar, alginic acid, calcium carbonate, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, crospovidone, polacrilin potassium, the starch glycolic is received, Rhizoma Solani tuber osi or tapioca, pregelatinized Starch, other starch, clay, other algin, other celluloses, natural gum, and composition thereof.
The lubricant that can be used for Pharmaceutical composition of the present invention and dosage form includes but not limited to: calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerol, sorbitol, mannitol, Polyethylene Glycol, other dihydroxylic alcohols, stearic acid, sodium lauryl sulphate, Pulvis Talci, hydrogenated vegetable oil (for example Oleum Arachidis hypogaeae semen, Cotton seed oil, Oleum helianthi, Oleum sesami, olive oil, Semen Maydis oil and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, and composition thereof.Other lubricant comprises: for example (AEROSIL 200 for silicate silica gel, W.R.Grace Co.ofBaltimore, MD produces), solidified gas colloidal sol (the Plano of synthetic silica, the DegussaCo. of TX sells), CAB-O-SIL (a kind of hot silica product that Cabot Co.of Boston MA sells), and composition thereof.If use, the amount of lubricant generally is less than Pharmaceutical composition that they added or 1% weight of dosage form approximately.
4.3.2. Slow release formulation
Controlled release method or releasing device administration that active component of the present invention can be known according to those of ordinary skills.Example includes but not limited to those methods or the device that following United States Patent (USP) is described: 3,845,770; 3,916,899; 3,536,809; 3,598,123; With 4,008,719,5,674,533,5,059,595,5,591,767,5,120,548,5,073,543,5,639,476,5,354,556 and 5,733,566, these patents are bonded to herein by reference.These dosage forms can for example wherein adopt hydroxypropyl emthylcellulose, other polymer backbone, gel, permeable membrane, osmosis system, multiple coatings, micropill, liposome, microsphere or its to make up the release profiles that the variable proportion that suits the requirements is provided with so that one or more active components slowly or controllably discharge.For active component of the present invention, can easily select the controlled release preparation (comprising those preparations described herein) that uses suitable those of ordinary skills to know.Therefore, the present invention includes the unit dosage forms that is applicable to oral administration, such as but not limited to the tablet that is applicable to controlled release, capsule, soft capsule and Caplet.
A common purpose of all controlled release drugs is that its non-controlled release preparation has better therapeutic effect relatively.The ideal effect that the application of the controlled release preparation of optimal design in treatment should reach is in the shortest time, to use minimum cured substance or control disease.The compliance that the advantage of controlled release preparation has the prolong drug activity, reduces administration number of times and improve the patient.In addition, controlled release preparation can be used to influence onset time or other character such as blood drug level for example, and the therefore generation of influence secondary (bad) effect.
Most controlled release preparation is configured to has following release characteristic: begin to discharge the dose (active component) that can produce desirable therapeutic effect rapidly, in the time that prolongs, discharge other dose gradually and continuously and keep prevention or therapeutical effect then.Stable for keeping intravital drug level, medicine must discharge from dosage form with certain speed, to remedy by metabolism and the dose that excretes from body.The controlled release of active component can be subjected to including but not limited to the stimulation of pH, temperature, enzyme, water or various conditions such as other physiological condition or chemical compound.
4.3.3. Parenteral dosage form
Can be subcutaneous through including but not limited to, the various approach of vein (comprising disposable large bolus injection), muscle and tremulous pulse, give the patient with parenteral dosage form. because the naturally defence of patient to pollutant generally avoided in their administration, therefore preferred parenteral dosage form be aseptic or give the patient before can sterilize. the example of parenteral dosage form includes but not limited to injection, is dissolved in or is suspended in injection dry product, injection suspension and the Emulsion in the pharmaceutically acceptable carrier.
Those skilled in the art know the suitable carriers applicable to parenteral dosage form of the present invention.Example includes but not limited to: water for injection (USP); Water carrier, such as but not limited to sodium chloride injection, ringer's inj, glucose injection, dextrose ﹠ sodium chloride injection and lactated ringer's inj; The mixable carrier of water, such as but not limited to ethanol, Polyethylene Glycol and polypropylene glycol; And nonaqueous carrier, such as but not limited to Semen Maydis oil, Oleum Gossypii semen, Oleum Arachidis hypogaeae semen, Oleum sesami, ethyl oleate, isopropyl myristate, and benzyl benzoate.
Also the chemical compound that can improve the dissolubility of one or more active components disclosed herein can be added in the parenteral dosage form of the present invention.
4.3.4 Percutaneous, part and mucosa dosage form
Percutaneous of the present invention, part and mucosa dosage form include but not limited to ophthalmic solution, spray, aerosol, ointment, lotion, ointment, gel, solution, Emulsion, suspensoid or other dosage form well known to those skilled in the art.Referring to, Remington ' sPharmaceutical Sciences for example, 16 editions and 18 editions, Mack publishes, Easton PA (1980 Nian ﹠amp; Nineteen ninety); With Introduction to Pharmaceutical Dosage Forms, 4 editions, Lea﹠amp; Febiger, Philadelphia (1985).The dosage form that is applicable to treatment oral mucosas tissue can be mixed with collutory or mouthful gel.In addition, the percutaneous dosage form comprises " storage type " or " matrix type " patch, can be applied to skin and can use one concrete period, so that make the active component of requirement infiltrate skin.
The suitable excipient (for example carrier and diluent) and the other materials of percutaneous, part and the mucosa dosage form that can be used for providing the present invention included are known by the pharmaceutical field technical staff, and the particular organization that will use according to given Pharmaceutical composition or dosage form and deciding.Consider this factor, use nontoxic and the acceptable representative excipient of pharmacy (including but not limited to water, acetone, ethanol, ethylene glycol, propylene glycol, 1,3 butylene glycol, isopropyl myristate, isopropyl palmitate, mineral oil and composition thereof) preparation lotion, tincture, ointment, Emulsion, gel or ointment.If desired, also humidizer or wetting agent can be added in Pharmaceutical composition and the dosage form.These add and help the example of component to know in this area.Referring to, Remington ' sPharmaceutical Sciences for example, 16 editions and 18 editions, Mack publishes, Easton PA (1980 and nineteen ninety).
According to concrete tissue to be treated, the auxilliary component that adds can used active component of the present invention to treat forward and backward or unite use.For example, penetration enhancers can be used for helping active component is released in the tissue.Suitable penetration enhancers includes but not limited to: acetone; Various alcohol, ethanol for example, oleyl alcohol and tetrahydrofurfuryl alcohol; Alkyl sulfoxide, for example dimethyl sulfoxine; Dimethyl acetylamide; Dimethyl formamide; Polyethylene Glycol; Ketopyrrolidine, for example polyvinylpyrrolidone; Kollidon level (polyvinylpyrrolidone (Povidone), polyvinylpyrrolidone (Polyvidone)); Carbamide; With various water solublity or water-insoluble sugar ester, for example Tween 80 (polysorbate80) and sorbester p18 (Arlacel-60).
Regulate the pH of the tissue that Pharmaceutical composition, dosage form or Pharmaceutical composition or dosage form use, can improve the release of one or more active components.Similarly, regulate polarity, its ionic strength or the tension force of solvent carrier, can improve release.Also the chemical compound as stearate (salt) can be added in Pharmaceutical composition or the dosage form, improve the hydrophilic or the lipotropy of one or more active components, thereby improve release.In this respect, stearate can be used as lipoid carrier, emulsifying agent or the surfactant of described preparation, and as release enhancers or penetration enhancers.Various salt, hydrate or the solvate of described active component can be used for further regulating the character of final composition.
4.3.5. Kit
Usually preferred active component of the present invention does not give the patient by identical approach simultaneously or not.Therefore, the present invention includes kit, when the clinicist used, described kit can make the active component of appropriate amount that patient's administration is oversimplified.
Representative medicaments box inclusion compound A of the present invention, or the unit dosage forms of the acceptable salt of its pharmacy, solvate, hydrate, clathrate, polymorph or prodrug, and the unit dosage forms of second kind of active component.The example of second kind of active component includes but not limited to those components that above-mentioned 4.2 parts are enumerated.
Kit of the present invention can further comprise the device that is used for the active component administration.The example of these devices includes but not limited to syringe, drip bag, eyeshield and inhaler.
Kit of the present invention can further comprise the pharmaceutically acceptable carrier that can be used for giving one or more active components.For example, if active component is a solid form, need must rebuild so that through parenteral, then described kit can comprise the sealed container of suitable carrier, and wherein said active component solubilized forms the agranular sterile solution that is applicable to through parenteral.The example of pharmaceutical acceptable carrier includes but not limited to: water for injection (USP); Water carrier, such as but not limited to sodium chloride injection, ringer's inj, glucose injection, dextrose ﹠ sodium chloride injection, and lactated ringer's inj; The mixable carrier of water, such as but not limited to ethanol, Polyethylene Glycol and polypropylene glycol; And nonaqueous carrier, such as but not limited to Semen Maydis oil, Oleum Gossypii semen, Oleum Arachidis hypogaeae semen, Oleum sesami, ethyl oleate, isopropyl myristate and benzyl benzoate.
5. embodiment
5.1 embodiment 1: 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4- Acetylamino isoindoline-1,3-diketone synthetic
With acetic acid (20ml) vlil of 1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethamine (1.0g, 3.7 mMs) under stirring and 3-acetylamino phthalic anhydride (751mg, 3.66 mMs) 15 hours.Remove under the vacuum and desolvate, obtain grease.Separate the oil that obtains by chromatography, obtain product (1.0g, yield 59%), be yellow solid, mp:144 ℃.
1H NMR(CDCl 3)δ1.47(t，J＝7.0Hz，3H，CH 3)，2.26(s，3H，CH 3)，2.88(s，3H，CH 3)，3.75(dd，J＝4.4，14.3Hz，1H，CHH)，3.85(s，3H，CH3)，4.11(q，J＝7Hz，2H，CH2)，5.87(dd，J＝4.3，10.5Hz，1H，NCH)，6.82-6.86(m，1H，Ar)，7.09-7.11(m，2H，Ar)，7.47(d，J＝7Hz，1H.，Ar)，7.64(t，J＝8Hz，1H，Ar)，8.74(d，J＝8Hz，1H，Ar)，9.49(br s，1H，NH)； 13C NMR(CDCl 3)δ14.61，24.85，41.54，48.44，54.34，55.85，64.43，111.37，112.34，l15.04，118.11，120.21，124.85，129.17，130.96，136.01，137.52，148.54，149.65，167.38，169.09，169.40；
C 22H 24NO 7S value of calculation: C, 57.38; H, 5.25; N, 6.08.Measured value: C, 57.31; H, 5.34; N, 5.83.
5.2 embodiment 2: (+) 2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl second Base]-4-acetylamino isoindoline-1,3-diketone synthetic
The preparation of 3-aminophthalic acid
Under blanket of nitrogen, with palladium on carbon (10%, 2.5g), 3-nitrophthalic acid (75.0g, 355 mMs) and ethanol (1.5L) adds in the Pa Er hydrogenator of 2.5L.Hydrogen is fed in the reaction vessel, reach 55psi to pressure.Vibrate this mixture 13 hours, and keep Hydrogen Vapor Pressure between 50-55psi.Get rid of hydrogen, and with nitrogen purge mixture 3 times.By Celite bed of diatomaceous earth filtering suspension liquid, and use methanol wash.Concentrated filtrate under the vacuum.The solid reuse ether that obtains is pulled an oar, and separate by vacuum filtration.The solid vacuum drying to constant weight, is obtained the 3-aminophthalic acid of 54g (yield 84%), be yellow solid.
1H-NMR(DMSO-d6)δ：3.17(s，2H)，6.67(d，1H)，6.82(d，1H)，7.17(t，1H)，8-10(brs，2H)。
13C-NMR(DMSO-d6)δ：112.00，115.32，118.20，131.28，135.86，148.82，169.15，170.09。
The preparation of 3-acetylamino phthalic anhydride
In the 1L three neck round-bottomed flasks that mechanical agitator, thermometer and condenser are housed, add 3-aminophthalic acid (108g, 596 mMs) and acetic anhydride (550mL).With reactant mixture reflux 3 hours, be cooled to ambient temperature then, again in 0-5 ℃ of cooling 1 hour down.Vacuum filtration is collected crystalline solid, and washs with ether.At ambient temperature with the solid vacuum drying to constant weight, obtain the 3-acetylamino phthalic anhydride of 75g (yield 61%), solid is white in color.
1H-NMR(CDCl 3)δ：2.21(s，3H)，7.76(d，1H)，7.94(t，1H)，8.42(d，1H)，9.84(s，1H)。
The fractionation of 2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine
In the 3L three neck round-bottomed flasks that mechanical agitator, thermometer and condenser are housed, add 2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine (137.0g; 500 mMs), N-acetyl group-L-leucine (52g, 300 mMs) and methanol (1.0L).Stir down slurry reflux 1 hour.Then under agitation, slurry is cooled to ambient temperature, and continues at ambient temperature to stir 3 hours.Filter slurry and use methanol (250mL) washing.Solid is dried, and vacuum drying obtains 109.5g crude product (85.8%ee (enantiomer is excessive), yield 98%) to constant weight at ambient temperature then.Crude product solid (55.0g) and methanol (440mL) were refluxed 1 hour together, be cooled to room temperature then, and restir 3 hours at ambient temperature.Filter slurry, with methanol (200mL) washing leaching cake.Solid is dried, then at 30 ℃ of following vacuum dryings to constant weight, obtain (S)-2-(3-ethyoxyl-4-methoxyphenyl)-1-(the mesyl)-second of 49.6g (response rate 90%)-2-base amine-N-acetyl group-L-leucine salt (98.4%ee).
Chirality HPLC (ethanol: 20mM KH 2PO 4=1: 99, pH is 7.0, the Ultron ES-OVS chiral column of Agilent company, and 150mm * 4.6mm, flow velocity are 0.5mL/min., the detection wavelength is 240nm): 18.4 minutes (isomer of S type, 99.2%), 25.5 minutes (isomer of R type, 0.8%).
The preparation of compd A
In the 500ml three neck round-bottomed flasks that mechanical agitator, thermometer and condenser are housed, add (S)-2-(3-ethyoxyl-4-methoxyphenyl)-1-(mesyl)-second-2-base amine-N-acetyl group-L-leucine salt (25g; 56 mMs; 98%ee), 3-acetylamino phthalic anhydride (12.1g, 58.8 mMs) and glacial acetic acid (250ml).Reaction mixture refluxed is spent the night, be cooled to then below 50 ℃.Remove under the vacuum and desolvate, then residue is dissolved in ethyl acetate.The solution that water (250ml * 2), saturated sodium bicarbonate aqueous solution (250ml * 2), saline (250ml * 2) washing obtain, and use dried over sodium sulfate.Evaporation removes and desolvates under the vacuum, the residue binary solvent recrystallization that contains ethanol (150ml) and acetone (75ml).Isolated by vacuum filtration goes out solid, and washs with ethanol (100ml * 2).Under 60 ℃ with the product vacuum drying to constant weight, obtain S-{2-[1-(3-ethyoxyl-4-the methoxyphenyl)-2-mesyl ethyl of 19.4g (yield 75%)]-4-aminoisoindoline-1,3-diketone (98%ee).
Chirality HPLC (ethanol: 20mM KH 2PO 4=15: 85, pH is 3.5, the Ultron ES-OVS chiral column of Agilent company, and 150mm * 4.6mm, flow velocity are 0.4mL/min., the detection wavelength is 240nm): 25.4 minutes (isomer of S type, 98.7%), 29.5 minutes (isomer of R type, 1.2%).
1H-NMR(CDCl 3)δ：1.47(t，3H)，2.26(s，3H)，2.87(s，3H)，3.68-3.75(dd，1H)，3.85(s，3H)，4.07-4.15(q，H)，4.51-4.61(dd，1H)，5.84-5.90(dd，1H)，6.82-8.77(m，6H)，9.46(s，1H). 13C-NMR(DMSO-d6)δ：14.66，24.92，41.61，48.53，54.46，55.91，64.51，111.44，112.40，115.10，118.20，120.28，124.94，129.22，131.02，136.09，137.60，148.62，149.74，167.46，169.14，169.48.
5.3. Embodiment 3:TNF-α suppresses
The mensuration that people's whole blood LPS-induces TNF-α
Chemical compound suppresses LPS-and induces the ability of people's whole blood TNF-α generation mainly to estimate by the method for lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α) among the following mensuration human PBMC, but use freshly extd whole blood to replace PBMC (George Muller etc., 1999, Bioorganic ﹠amp; Medicinal Clemistry Letters, 9 phases: the 1625-1630 page or leaf).People's whole blood LPS-induces the IC of TNF-α 50Be 294nM.
The inhibition of the blood serum induced TNF-α of mice LPS-
According to the method for former description (Corral etc., 1996, Mol.Med, 2 phases: the 506-515 page or leaf), with described animal model test compounds.Inhibition (the ED of the blood serum induced TNF-α of mice LPS- 50, mg/kg, p.o.)=0.05.
LPS-induces the generation of TNF-α
Lipopolysaccharide (LPS) is a kind of endotoxin that is produced by the gram-negative bacteria as escherichia coli (E.coli), and LPS can induce and produce the multiple proinflammatory cytokine that comprises TNF-α.In peripheral blood lymphocytes (PBMC), the TNF-α that replys the LPS generation originates from mononuclear cell, accounts for the 5-20% of total PBMC.According to preceding method (Muller etc.,, J.MedChem., 39 phases: 3238 pages in 1996), measure chemical compound and suppress the ability that LPS-induces human PBMC's TNF-α generation.By Ficoll Hypaque (Pharmacia, Piscataway, NJ, USA) Density Gradient Centrifugation obtains PBMC from normal donors.Cell is placed RPMI (LifeTechnologies, Grand Island, the USA New York) cultivates in, add 10%AB ± type human serum (Gemini Bio-products, Woodland, CA, USA), 2mM L-glutamine, 100U/ml penicillin and 100 μ g/ml streptomycins (Life Technologies).
PBMC (2 * 10 5Cell) be tiled in 96-hole flat Costar tissue culturing plate (Corning, New York, USA), triplicate.With the LPS that adds or do not add the 100ng/ml of chemical compound (Sigma, St.Louis, MO, USA) irritation cell.With chemical compound (NJ USA) is dissolved among the DMSO (Sigma) for Celgene Corp., Warren, face with before, in culture medium, further dilute immediately.In whole samples, the DMSO final concentration is 0.25%.Before LPS stimulates 1 hour, chemical compound is added in the cell.Under 37 ℃, 5% carbon dioxide conditions cultured cell 18-20 hour, collect supernatant then, with the culture medium dilution, and by ELISA (MA USA) measures TNF-α concentration for Endogen, Boston.LPS-induces the IC of TNF-α 50=77nM.
IL-1 β-the induce generation of TNF-α
In the process of inflammatory diseases, normally the LPS of cytokine IL-1 β rather than bacterial derivation stimulates TNF-α to generate.Induce the method for TNF-α generation according to above-mentioned LPS-, measure chemical compound and suppress IL-1 β-the induce ability of the generation of human PBMC TNF-α, but PBMC is by Ficoll-Paque Plus (Amersham Pharmacia, Piscataway, NJ, USA) centrifugal, from source leukocyte unit (Source leukocyte unit) (Sera-Tec Biologicals, NorthBrunswick, NJ, USA) separate obtaining in, with 3 * 10 5The density of cells/well, PBMC is tiled in 10% the heat-inactivated hyclone (Hyclone) of comprising in the tissue culturing plate of 96-hole, 2mM L-glutamine, RPMI-1640 culture medium (the Bio Whittaker of 100U/ml penicillin and 100mg/ml streptomycin (complete medium), Walkersville, Maryland, USA) in, at 37 ℃, under 5% the carbon dioxide conditions, in moistening incubator, be 10 with concentration respectively, 2,0.4,0.08,0.016,0.0032,0.00064 and the chemical compound (the DMSO final concentration is 0.1%) of 0 μ M, duplicate pretreatment 1 hour uses the recombined human IL-1 β (Endogen) of 50ng/ml to stimulate then 18 hours.IL-1 β-the induce IC of TNF-α 50=83nM.
5.4. embodiment 4:PDE selectivity
The mensuration of PDE1,2,3,5 and 6 enzymes
The anti-cattle PDE1 of chemical compound by measuring single concentration (10 μ M), from people PDE2, PDE3 and PDE5 (Hidaka and the Asano of human blood platelets, 1976, Biochem.Biophys.Acta, 429 phases: 485 pages, with Nicholsen etc.,, Trends Pharmaco.Sci., 12 phases: 19 pages in 1991) and from the PDE6 (Baehr etc. of cattle retinal rod acromere, 1979, J.Biol.Chem., 254 phases: 11669 pages and Gillespie etc., 1989, Mol.Pharm. activity, 36 phases: 773 pages) is come the selection specificity of assessing compound to PDE4.The results are shown in the table 1.
The mensuration of PDE7 enzyme
PDE7 is a kind of mainly at the T cellular expression and be present in cAMP-selectivity PDE in the skeletal muscle.Suppress the cytokine of cell-derived for example IL-2 of scalable T and IFN-γ by PDE7.Adopt previously described anion-exchange chromatography (Bloom and Beavo, 1996, Proc.Natl.Acad Sci.USA, 93 phases: the 14188-14192 page or leaf), Hut78 human T-cell purification is obtained PDE7, with in the following table 1 to the description of PDF4, in the presence of the cAMP of 10nM, the activity of the anti-PDE7 preparation of test compounds.
Table 1.
Figure G2006101374074D00351
* compd B is the enantiomer of compd A.
5.5. Embodiment 5:PDE4 suppresses
The mensuration of PDE4 (cell-derived) enzyme by U937
According to aforementioned gel-filtration chromatography (Muller etc.,, Bioorg.﹠amp in 1998; Med ChemLett, 8 phases: the 2669-2674 page or leaf), U937 person monocytic cell purification is obtained the PDE4 enzyme.Under 30 ℃ 50mM Tris-HCl (pH is 7.5), 5mM MgCl 2, 1 μ M cAMP, 10nM[ 3H]-cAMP in, carried out the di-phosphate ester enzyme reaction 30 minutes, then by boiling termination, handle, and according to preceding method (Muller etc.,, Bioorg.﹠amp in 1998 with the snake venom of 1mg/ml; MedChem Lett, 8 phases: the 2669-2674 page or leaf), separate with AG-1XS ion exchange resin (BioRad).
Effective substrate of reaction consumes is below 15%.The results are shown in the table 1.
5.6. Embodiment 6: human T-cell's mensuration
SEB induces the generation of IL-2 and IFN-γ
Staphylococcal enterotoxin B (SEB) is the deutero-superantigen of gram positive bacteria-staphylococcus aureus (Staphylococcus aureus).SEB provides a kind of special TXi Baoshouti V β chain to the T cellular expression to have specific physiological stimulation easily.According to the method described above, with human PBMC's (the T cell by about 50% is formed) from source leukocyte units separate, and with 3 * 10 5The concentration of cells/well, be tiled in the complete medium of 96 hole tissue culturing plates, under 37 ℃, 5% carbon dioxide conditions, in moistening incubator, with concentration respectively the chemical compound (the DMSO final concentration is 0.1%) of 10,2,0.4,0.08,0.016,0.0032,0.00064 and 0 μ M, duplicate pretreatment 1 hour, use SEB (the Sigma Chemical Co. of 100ng/ml then, St.Louis, MO USA) stimulated 18 hours.By ELISA (R﹠amp; D Systems, Minneapolis, MN, USA) concentration of mensuration IL-2 and IFN-γ.The IC of IL-2 50=291nM, the IC of IFN-γ 50=46nM.
5.7. The mensuration that embodiment 6:cAMP raises
PGE2-induces cAMP to raise
With prostaglandin E 2(PGE 2) be bonded on the prostaglandin receptor on mononuclear cell, T cell and other leukocyte, improved the level of cAMP in the cell subsequently, cause having suppressed cell response.PGE 2With the intracellular cAMP level of collaborative these types that raise of the combination of PDE4 inhibitor, and at PGE 2Exist down, the cAMP level in the PBMC that the PDE4 inhibitor causes raises and is directly proportional with the inhibition activity of these PDE4 inhibitor.Measure human PBMC's intracellular cAMP by the following method: separate PBMC as stated above, and with 1 * 10 6The concentration of cells/well is tiled in the RPMI-1640 culture medium of 96 well culture plates.Under 37 ℃, 5% carbon dioxide conditions, in moistening incubator, with concentration respectively the chemical compound (the DMSO final concentration is 2%) of 100,10,1,0.1,0.01 and 0 μ M, duplicate pretreatment cell 1 hour.Use PGE then 2(10 μ M) (Sigma) stimulated 1 hour.With HCl (final concentration is 0.1N) dissolved cell,, then culture plate is placed-20 ℃ to descend freezing so that suppress the activity of phosphodiesterase.Use cAMP (low pH) immunoassay kit (R﹠amp; DSystems) measure the cAMP that generates.The PBMC cAMP EC of raceme 50Be 3.09 μ M, the PBMC cAMP EC of compd A 50Be 1.58 μ M.
Measure the rising of the cAMP in people's neutrophil cell by the following method: centrifugal by Ficoll-Paque Plus (Amersham Pharmacia), PBMC is separated from source leukocyte (Sera-TecBiologicals).Erythrocyte/polymorphonuclear cell (PMN) granular sludge that obtains is resuspended in the Hank ' s balanced salt solution (BioWhittaker), and mixes with 3% the dextran T-500 (Amersham Pharmacia) that is dissolved in 0.9% normal saline of equal volume.
With erythrocyte sedimentation 20 minutes, separate PMN then, and under 4 ℃ centrifugal 8 minutes with the rotating speed of 120rpm. with remaining erythrocytolysis in cold 0.2% normal saline 30 seconds, and add 1.6% normal saline of equal volume, these cells are restored to waiting ooze. under 4 ℃ with the centrifugal PMN of the rotating speed of 1200rpm 8 minutes, and then be suspended among the RPMI-1640, and, measure the rising of cAMP according to above-mentioned PBMC assay method.Use FACSCalibur (Becton Dickinson, San Jose, CA, flow cytometry USA) is measured, and the result shows that PMN is about 74%CD18/CD11b +, 71%CD16 +CD9 +Neutrophil cell.The result lists in the table 2.
FMLF-induces the generation of LTB4
N-formoxyl-methionine-Ile-Phe (fMLF) is a kind of bacterial derivation peptide; it activates neutrophil cell threshing promptly, moves, adheres on the endotheliocyte, and discharges leukotriene LTB4 (a kind of arachidonic metabolite and himself are a kind of neutrophil cell chemistry attractant).According to preceding method (Hatzelmann and Schudt, calendar year 2001, J.Pharm.Exp.ther., 297 phases: the 267-279 page or leaf) and following improving one's methods, the ability of the generation of the inductive neutrophilia LTB4 of test compounds blocking-up fMLF-.Separate neutrophil cell according to the method described above, and be resuspended in the phosphate buffered saline (PBS) (Bio Whittaker) that contains 10mM HEPES (pH is 7.2) of no calcium or magnesium, then with 1.7 * 10 6The concentration of cells/well is tiled in 96 well culture plates.Under 37 ℃, 5% carbon dioxide conditions, with thimerosal (Sigma)/1mM CaCl of 50 μ m 2/ l mM MgCl 2Handled cell 15 minutes, then respectively with concentration be 1000,200,40,8,1.6,0.32,0.064 and the chemical compound (the DMSO final concentration is 0.01%) of 0nM handled in duplicate 10 minutes.Stimulate neutrophil cell 30 minutes with the fMLF of 1 μ m, add methanol (final concentration is 20%) dissolving then, and in dry ice/isopropanol is bathed freezing 10 minutes.Preserve lysate at-70 ℃, until passing through competitive LTB4ELISA (R﹠amp; D Systems) content of mensuration LTB4.The result is as shown in table 2.
Zymosan-the induce generation of IL-8
Zymosan A or heat-inactivated saccharomyces cerevisiae (Saccharomyces cerevisiae) are bonded on the Mac-1 adhesion molecule on neutrophil cell surface, and cause engulf, cell activation and IL-8 generate.According to preceding method (Au etc., 1998, the Brit.J.Pharm.123 phase: the 1260-1266 page or leaf) and following improving one's methods measure the inductive IL-8 of zymosan and generate.Purification people neutrophil cell as stated above is with 3 * 10 5The concentration of cells/well, be tiled in the complete medium of 96 hole tissue culturing plates, under 37 ℃, 5% carbon dioxide conditions, be respectively the chemical compound (the DMSO final concentration is 0.1%) of 10,2,0.4,0.08,0.016,0.0032,0.00064 and 0 μ M with concentration, handled in duplicate 1 hour.Use zymosan A (Sigma) conditioning, that do not boil with 2.5 * 10 then 5The concentration in granule/hole stimulated neutrophil cell 18 hours.The results supernatant, and by ELISA (R﹠amp; D Systems) test I L-8.The result is as shown in table 2.
FMLF-induces the expression of CD18/CD11b
The 308-317 page or leaf) and do following change according to preceding method (Derian etc., nineteen ninety-five, J.Immunol., 154 phases:, be determined at the CD18/CD11b (Mac-1) that expresses on the neutrophil cell.Separate neutrophil cell as stated above, then with 1 * 10 6The concentration of cell/ml is resuspended in the complete medium, and under 37 ℃, 5% carbon dioxide conditions, is respectively the chemical compound (the DMSO final concentration is 0.1%) of 10,1,0.1,0.01 and 0 μ M, duplicate pretreatment 10 minutes with concentration.Use 30nM fMLF irritation cell 30 minutes then, and be cooled to 4 ℃.With rabbit igg (Jackson ImmunoResearch Labs, West Grove, PA, USA) (10 μ g/1 * 10 6Cell) handles cell with blocking-up Fc receptor, dye with CD18-FITC and CD11b-PE (Becton Dickinson), and analyze by the flow cytometry on the FACSCalibur.The CD18/CD11b of deduction during non-stimulated the existence expresses (mean fluorecence) from whole samples, the curve that is inhibited, and calculate IC 50Value.The result is as shown in table 2.
FMLF-induces the adhesion on HUVEC
According to preceding method (Derian etc., nineteen ninety-five, J.Immunol., the 308-317 page or leaf) and do following change 154 phases:, Human umbilical vein endothelial cells (HUVEC) is used as the substrate .HUVEC cell of neutrophil cell adhesion from Anthrogenesis (Cedar Knolls, NJ, USA), and neutrophil cell is handled without cell division chalone B.Be respectively the chemical compound (the DMSO final concentration is 0.1%) of 10,1,0.1,0.01,0.001 and 0 μ M with concentration, duplicate processing cell 10 minutes, stimulated 30 minutes with 500nM fMLF then, and using the board-like reader of FLX800 (Bio-Tek Instruments, Winooski, VT USA) before the mensuration fluorescence, uses the PBS washed twice.The result is as shown in table 2.
Table 2
People's neutrophil cell is measured (all numerical value is all in nM) Racemic compound Compd A
PGE 2-induce the EC of cAMP 50 12589 4570
FMLF-induces the IC of LTB4 50 20.1 2.48
The IC of zymosan-inductive IL-8 50 ND 94
The IC that fMLF-induces CD18 to express 50 ND 390
The IC that fMLF-induces CD11b to express 50 ND 74
FMLF-induces the IC that adheres on the HUVEC 50 ND 150
5.8. Embodiment 8: water-soluble
In being 7.4 aqueous buffer solution, pH measures equilbrium solubility.PH is 7.4 buffer solution by with the NaOH of the 10N NaH with 0.07M 2PH regulator to 7.4 preparation of PO4 solution.The ionic strength of this solution is 0.15.At least the powder of 1mg is mixed with the buffer of 1ml, and preparation concentration is greater than the mixture of 1mg/ml.These samples were swayed above 2 hours, and at room temperature place and spend the night.Then by using the nylon syringe filter filtered sample of 0.45 saturated μ m of sample earlier.Continuous sampling is twice from filtrate.Make reference with the standard solution that in 50% methanol, prepares, measure filtrate by HPLC.The water solubility of compd A is bigger 3.5 times than racemic mixture.The solubility results of measuring is: compd A=0.012mg/ml; Racemic mixture=0.0034mg/ml.
5.9. The ferret model of the inductive lung neutrocytophilia of embodiment 8:LPS
When the by oral route administration, conscious ferret model is used to study the antiinflammatory of PDE4 inhibitor, emetic and behavior effect.According to these experiments, can determine the therapeutic index (TI) of each PDE4 inhibitor.The TI value is calculated divided by antiinflammatory dosage (dosage that suppresses the inductive neutrocytophilia 50% of LPS-) by the threshold dose that causes emetic outbreak and behavior change.
Animal feeding
Hob (Mustela Pulorius Euro, body weight 1-2kg).Ferret is provided by Bury GreenFarm or Misay Consultancy.After ferret is shipped, conform at least 7 days time at receptacle earlier.Food comprises the granular SDS feedstuff C that can arbitrarily feed, and the Whiskers cat food of feeding 3 times weekly.Water is the animal level drinking water that pasteurizes, and change every day.
The administration of PDE4 inhibitor
The administration of PDE4 inhibitor oral administration, predose is 1-10mg/kg, but increase to 30mg/kg later on, so that determine whether TI is 10 or higher, and/or with the definite minimum dose that suppresses neutrocytophilia 50% of lower dosage. forbid feeding ferret evening, but allow freely to drink water. enter the Dosage syringer of the 15cm of esophagus by back through larynx, give this animal with PDE4 inhibitor or carrier per os approach. after the administration, ferret is sent back in the rearging cage of being furnished with the Perspex organic glass door, so that observe, and ferret can freely drink water. after the administration, observe ferret continuously, and write down the change of any vomiting or behavior. after oral administration 60-90 minute, allow the ferret feed.
Be exposed among the LPS
Oral administration of compound or control vector placed the Perspex lucite container of sealing with ferret after 30 minutes, and were exposed in LPS (the 100 μ m/ml) aerosol 10 minutes.(De Vilbiss USA) produces the LPS aerosol, and directly sprays in the described Perspex lucite exposure chamber by aerosol apparatus.Expose after 10 minutes, send ferret back to rearging cage, and allow freely to intake, and, allow feed in later phases.Behind the oral administration, observed at least 2.5 hours continuously, and write down emetic outbreak and behavior change.
Bronchoalveolar lavage
Be exposed among the LPS after 6 hours, give excessive pentobarbital sodium, ferret is put to death through the abdominal cavity.Insert polypropylene tube at trachea then, and with 20ml heparinization (twice in phosphate buffered solution (PBS) the lavation lung of 10 units/ml).
Blood sample/cutting tissue
Through the breast cardiac puncture, terminal blood sample (10ml) is excised., remove blood plasma and place-20 ℃ to preserve down centrifugal 15 minutes of blood sample with the rotating speed of 2500rpm.Be analysis of compounds content, also with decerebration, and freezing under placing-20 ℃.
Cell counting
With the rotating speed of 1500rpm, with centrifugal 15 minutes of the sample of bronchoalveolar lavage (BAL).Remove supernatant then, and the cell granulations shape thing that obtains is resuspended among the PBS of 1ml.The cell smear of preparation heavy suspension, and with the dyeing of Leishmans coloring agent, so that the cell divide counting.Resuspension sample by remainder is determined total cellular score.Based on this, can determine the sum of neutrophil cell among the BAL.
Parametric measurement
1.LPS the inhibition % of inductive lung neutrocytophilia.
2. the vomiting of emetic outbreak-record and retch number of times.
3. the following behavior outcome of behavior change-record: the stream birth, mouth is grabbed in tachypnea, position flattens, coordination can not, hogback and backward.That half is carried out in arbitrary behavior change wherein is quantitative by using severity rank (slight, moderate and serious).
4. with the maximal dose of finding that does not cause emetic outbreak, divided by suppressing lung neutrocytophilia 50% or above lowest dose level calculating TI.
Compd A is to the effect of LPS-inductive neutrocytophilia in the lung of conscious ferret, as shown in Figure 1.
Vomiting and behavior change
In vain. after the weasel oral administration gives PDE4, observed at least 2 hours, and write down emetic outbreak (vomiting and retch) and behavior variation.
The ferret of orally give respective carrier (acetone/cremophor/ distilled water) does not observe emetic outbreak (vomiting and retch) in advance.Discovery has the ferret (7/22) of minority control treatment slight behavior change (licking lip and backward) to occur.
Compd A (0.1-3mg/kg, oral) do not cause emetic outbreak (vomiting and retch). only observe some and be classified as slight behavior change (position flattens, licks lip and backward). when dosage is 10mg/kg, discovery has 2/6 ferret appearance retch (not being direct vomiting), observe stream birth and behavior change (keep the score and be slight or moderate) simultaneously. when the maximum dose level (30mg/kg) of experiment, observing 3/4 ferret has moderate to arrive significant vomiting, and significant behavior change is arranged.
These data have been summed up in the Table III.
Table III. conscious ferret: emetic outbreak and behavior change behind the orally give compd A.
Processing/dosage (mg/kg) Vomiting Retch The stream birth Tachypnea Grab mouth Position flattens Coordination can not Lick lip Backward
Carrier (acetone/cremophor/ distilled water) Do not have Do not have Do not have Do not have Do not have Do not have Do not have Slightly (6/22) Slightly (7/22)
Compd A (0.1mg/kg) Do not have Do not have Do not have Do not have Do not have Slightly (2/5) Do not have Slightly (4/5) Slightly (3/5)
Compd A (0.3mg/kg) Do not have Do not have Do not have Do not have Do not have Slightly (2/6) Do not have Slightly (3/6) Slightly (4/6)
Compd A (1.0mg/kg) Do not have Do not have Do not have Do not have Do not have Slightly (2/6) Do not have Slightly (6/6) Slightly (4/6)
Compd A (3.0mg/kg) Do not have Do not have Do not have Do not have Slightly (1/8) Significantly (7/8) Do not have Slightly (2/8) Moderate (5/8)
Compd A (10mg/kg) Do not have Slightly (2/6) Slightly (1/6) Do not have Slightly (1/6) Significantly (6/6) Do not have Moderate (5/6) Significantly (6/6)
Compd A (30mg/kg) Moderate (3/4) Significantly (3/4) Moderate (3/4) Slightly (1/4) Significantly (4/4) Significantly (4/4) Slightly (3/4) Moderate (4/4) Slightly (2/4)
After the administration, observe ferret and reach 3 hours.Numeral in the bracket is meant the ferret number that reaction occurs.Every group ferret number is 4-22.
Therapeutic index calculates
According to these experiments, with the ED of the threshold dose of inducing emetic outbreak divided by inhibition lung neutrocytophilia 50, can determine the therapeutic index (TI) of every kind of chemical compound.TI result of calculation is summarised in the Table IV.The TI of compd A is 12, under the antiinflammatory dosage of 1mg/kg, can not cause emetic outbreak.
Table IV. suppress the effective dose (ED of the inductive lung neutrocytophilia of LPS- 50), induce vomiting and according to the summary of the therapeutic index of these data computation.
Chemical compound Inhibition (the ED of the inductive neutrocytophilia of LPS 50mg/kg) Emetic threshold dose (mg/kg) Therapeutic index
Compd A 0.8 10 12
5.10. The capsule of embodiment 9:200mg dosage
Table V is for example understood batch prescription and the single dose prescription of the unit dose of 200mg compd A, promptly about 40% weight, and No. 0 capsule is filled.
Table V .200mg capsule prescription
Raw material % weight Quantity (mg/ sheet) Quantity (kg/ criticizes)
Compd A 40.0％ 200mg 16.80kg
Pregelatinized corn starch, NF5 9.5％ 297.5mg 24.99kg
Magnesium stearate 0.5％ 2.5mg 0.21kg
Altogether 100.0％ 500mg 42.00kg
Pregelatinized Starch (SPRESS B-820) and compd A component are crossed 710 μ m sieve, be put in then and have in the diffusion type blender that inserts baffle plate, mixed 15 minutes.Magnesium stearate is crossed 210 μ m sieve, and add in the described diffusion type blender.Use Dosator type capsule filling machine, with No. 0 capsule charge mixture, every capsules is 500mg (every batch 8400 capsules).
5.11. Embodiment 10:100mg peroral dosage form
Table VI is for example understood batch prescription and the unit dose prescription that comprises the 100mg compd A.
Table VI .100mg tablet recipe
Raw material % weight Quantity (mg/ sheet) Quantity (kg/ criticizes)
Compd A 40％ 100.00 20.00
Microcrystalline Cellulose, NF 53.5％ 133.75 26.75
Pluronic F-68 surfactant 4.0％ 10.00 2.00
A type cross-linked carboxymethyl cellulose sodium, NF 2.0％ 5.00 1.00
Raw material % weight Quantity (mg/ sheet) Quantity (kg/ criticizes)
Magnesium stearate, NF 0.5％ 1.25 0.25
Altogether 100.0％ 250.00mg 50.00kg
Microcrystalline Cellulose, cross-linked carboxymethyl cellulose sodium and compd A component are crossed 30 mesh sieves (about 430 μ-655 μ).With Pluronic F-
Figure G2006101374074D00451
(the RH Biosciences of KS.Lenexa, Inc. produces) surfactant is crossed 20 mesh sieves (about 457 μ-1041 μ).With Pluronic F-
Figure G2006101374074D00452
Surfactant and 0.5kg cross-linked carboxymethyl cellulose sodium add in 16 quarts the bipyramid roller mixer, and mix about 5 minutes.Mixture transferred in 3 cubic feet the bipyramid roller mixer, add microcrystalline Cellulose, and mixed about 5 minutes.Add Thalidomide, remix 25 minutes.This pre-composition is granulated through the dry type pressure roller comminutor that articulates beater grinder at discharging opening, and then returns in the described shaker mixer.Remaining cross-linked carboxymethyl cellulose sodium and magnesium stearate are added in the roller mixer, and mixed about 3 minutes.Final mixture rotary tablet machine tabletting, sheet heavily are 250mg/ sheet (200,000 every crowd).
5.12. Embodiment 11: aerosol dosage forms
The isceon of compd A and 12.6kg is mixed the preparation concentrated solution in the sealing rustless steel container that is equipped with high shear mixer.Mix and carried out about 20 minutes.With the propellant of described concentrated solution and aequum, be controlled at 21 ℃-27 ℃, pressure in temperature and be controlled in the batch process jar of 2.8-4.0bar, be mixed with suspension in batches.Use has the 17ml aerosol container of a metering valve, and it is designed to provide the suction volume of 100 deuterzooid inventive compositions.Every container contains following component:
Compd A 0.0120g
Isceon 1.6939g
Dichlorodifluoromethane 3.7175g
Dichlorotetra-fluoroethane 1.5766g
7.0000g altogether
Though adopted specific embodiment that the present invention is made description, to those skilled in the art, various possible changes and modification are conspicuous, do not depart from claims of the present invention and limited aim and scope.These revise the scope that also will fall into additional claims.

Claims (33)

1. (+) that stereoisomer is pure-2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1, the 3-diketone, or its pharmaceutically acceptable salt is used for the treatment of purposes in the medicine of cancer in preparation.
2. the purposes of claim 1, wherein said medicine also comprises antineoplastic agent.
3. the purposes of claim 1, wherein said antineoplastic agent is alkylating agent, jnk inhibitor, antibiotic, aziridine, methylmelamine, alkyl sulfonate esters, nitroso ureas, triazenes, vinca alkaloids, epipodophyllotoxin.
4. the purposes of claim 1, wherein said alkylating agent is a chlormethine.
5. the purposes of claim 1, wherein said cancer is a solid tumor.
6. the purposes of claim 1, wherein said cancer is the blood tumor.
7. the purposes of claim 1, wherein said cancer is multiple myeloma, acute leukemia, chronic leukemia, lymphoblastic leukemia, myelomatosis, Lymphocytic leukemia or myelocytic leukemia.
8. the purposes of claim 5, wherein said solid tumor is lacteal tumor, colon tumor, rectum tumor, colorectum tumor, nephroncus or glioma.
9. the purposes of claim 1, wherein said medicine is through parenteral, percutaneous, mucosa, nose, mouthful cheek, Sublingual or mouthful administration.
10. the purposes of claim 9, wherein said medicine oral administration.
11. the purposes of claim 10, wherein said medicine is with tablet or Capsule form oral administration.
12. the purposes of claim 11, the treatment effective dose of wherein said medicine are 1mg-1000mg every day.
13. the purposes of claim 12, the treatment effective dose of wherein said medicine are 5mg-500mg every day.
14. the purposes of claim 13, the treatment effective dose of wherein said medicine are 10mg-200mg every day.
(+) that 15. stereoisomer is pure-2-[1-(3-ethyoxyl-4-methoxyphenyl)-2-mesyl ethyl]-4-acetylamino isoindoline-1; the 3-diketone, or its pharmaceutically acceptable salt is used for the treatment of purposes in the medicine of depression, dermatitis, psoriasis, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (sle), enteritis or Behcet disease in preparation.
16. the purposes of claim 15, wherein said medicine is used for the treatment of psoriasis.
17. the purposes of claim 15, wherein said medicine is used for the treatment of rheumatoid arthritis.
18. the purposes of claim 15, wherein said dermatitis are atopic dermatitis or contact dermatitis.
19. the purposes of claim 15, wherein said enteritis are Crohn disease or colitis.
20. any one purposes among the claim 15-19, wherein said medicine also comprises antihistaminic, anti-inflammatory agent or steroid drugs.
21. the purposes of claim 20, wherein said anti-inflammatory agent are NSAID (non-steroidal anti-inflammatory drug).
22. any one purposes among the claim 15-19, wherein said medicine is through parenteral, percutaneous, mucosa, nose, mouthful cheek, Sublingual or mouthful administration.
23. any one purposes among the claim 15-19, wherein said medicine oral administration.
24. the purposes of claim 23, wherein said medicine is with tablet or Capsule form oral administration.
25. having, any one purposes among the claim 15-19, the treatment of wherein said medicine high-volume be 1mg-1000mg every day.
26. the purposes of claim 25, the treatment effective dose of wherein said medicine are 5mg-500mg every day.
27. the purposes of claim 26, the treatment effective dose of wherein said medicine are 10mg-200mg every day.
28. the purposes of claim 7, wherein said Lymphocytic leukemia are chronic lymphocytic leukemia.
29. the purposes of claim 1 or 15, wherein said medicine is through topical.
30. the purposes of claim 29, wherein said medicine is with ophthalmic solution, spray, aerosol, ointment, lotion, ointment, gel, solution, Emulsion or suspensoid form administration.
31. the purposes of claim 30, the treatment effective dose of wherein said medicine are 1mg-1000mg every day.
32. the purposes of claim 31, the treatment effective dose of wherein said medicine are 5mg-500mg every day.
33. the purposes of claim 32, the treatment effective dose of wherein said medicine are 10mg-200mg every day.
CN2006101374074A 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound Expired - Lifetime CN1965823B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36651502P 2002-03-20 2002-03-20
US60/366515 2002-03-20
US43845003P 2003-01-07 2003-01-07
US60/438450 2003-01-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038110938A Division CN100427085C (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Publications (2)

Publication Number Publication Date
CN1965823A CN1965823A (en) 2007-05-23
CN1965823B true CN1965823B (en) 2010-05-12

Family

ID=38074916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006101374074A Expired - Lifetime CN1965823B (en) 2002-03-20 2003-03-20 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound

Country Status (2)

Country Link
CN (1) CN1965823B (en)
ZA (1) ZA200600682B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898349A (en) * 2008-03-27 2013-01-30 细胞基因公司 Solid containing compound, a composition containing the solid and use of the solid
CN104910062A (en) * 2015-05-16 2015-09-16 南京海纳医药科技有限公司 Apremilast refining method
CN105085373B (en) * 2015-09-01 2018-02-09 苏州大学 Purification method of apremilast product
CN111821297A (en) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases
CN115068491A (en) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 Medical application of andrographolide as LTB4 receptor inhibitor
CN114790164B (en) 2021-08-13 2022-12-27 苏州璞正医药有限公司 Substituted isoindoline-1,3-diketone PDE4 inhibitor and pharmaceutical application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
CN1965823A (en) 2007-05-23
ZA200600682B (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CN100427085C (en) (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR20150038547A (en) Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR20050086715A (en) Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN1965823B (en) (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound
CN102702070A (en) Solid form containing (+)-2-[1-(3-oxethyl-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, composition and application thereof
KR20050075435A (en) Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN102898349A (en) Solid containing compound, a composition containing the solid and use of the solid
AU2007231843A1 (en) Tooth Whitening Products

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103985

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1103985

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20200720

Address after: Richter rothkluz, Switzerland

Patentee after: Amgen (Europe) Ltd.

Address before: New jersey, USA

Patentee before: CELGENE Corp.

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20100512

CX01 Expiry of patent term